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Background: Tuberculous meningitis (TBM) is a devastating infection of the central nervous 24 
system lacking  an adequate point-of-care diagnostic test.  25 
Methods: We conducted a prospective cohort study of 550 Zambian adults with suspected 26 
TBM to determine the diagnostic accuracy of cerebrospinal fluid (CSF) Xpert MTB/RIF, CSF 27 
lipoarabinomannan (LAM), Urine LAM, CSF total protein, and CSF glucose compared to the 28 
gold standard of CSF culture. We categorized patients with a positive CSF tuberculosis (TB) 29 
culture as definite TBM. We also assessed inpatient and one-year mortality on definite TBM 30 
patients when CSF Xpert MTB/RIF results were available in real-time to treating physicians 31 
relative to a historical comparison cohort in whom Xpert results were not available in real-32 
time. 33 
Results: Of the 550 patients, 474 (86.2%) were HIV-infected and 105/550 (19.1%) had 34 
definite TBM based on a positive CSF culture. The sensitivity/specificity of the diagnostic 35 
tests were CSF Xpert MTB/RIF 52.9%/94.2%, CSF LAM 21.9%/94.2%, urine LAM 36 
24.1%/76.1%, CSF glucose < 40 mg/dL and total protein > 100 mg/dL 66.3%/90%. A model 37 
including CSF Xpert MTB/RIF, CSF LAM, CSF glucose, and CSF total protein demonstrated an 38 
area under the receiver operating curve of 0.90. The inpatient and one-year mortality for 39 
definite TBM was 43% and 57%. 40 
Conclusions: There was low sensitivity for the diagnosis of TBM across all diagnostics tests. 41 
CSF Xpert MTB/RIF and CSF LAM are highly specific for the diagnosis of TBM. Despite the use 42 
of Xpert MTB/RIF for diagnostic purpose in real-time, TBM was still associated with a high 43 













































Introduction  49 
TBM is a devastating infection of the central nervous system often leading to severe 50 
neurological impairment and death. Its effects are even more profound in sub-Saharan 51 
Africa where HIV is endemic. The diagnosis of TBM is problematic regardless of setting. CSF 52 
acid-fast bacteria staining has a sensitivity of 10-20% that varies greatly based on technical 53 
expertise.(1) CSF Mycobacterium tuberculosis (M. tuberculosis) culture is widely considered 54 
to be an imperfect gold standard with a sensitivity from 50-70%(2, 3) and can take as long as 55 
six weeks to become positive. Neither of these techniques is practical in many low and 56 
middle-income countries (LMIC) due to the complexity of widely instituting a specialized 57 
laboratory skill and the lack of effective systems to communicate results to patients in the 58 
community. As a result, treatment is often initiated empirically, with a lack of supportive 59 
diagnostic testing.  60 
Xpert MTB/RIF is an automated real-time PCR platform that provides a diagnosis of TBM 61 
and rifampicin resistance through analysis of CSF in under 2 hours. In 2013, the World 62 
Health Organization endorsed Xpert MTB/RIF as the initial test for the diagnosis of TBM after 63 
a review of multiple studies which demonstrated a sensitivity of 60% and specificity of 95% 64 
in comparison to CSF culture.(4) Interestingly, no study to date has demonstrated that the 65 
use of Xpert MTB/RIF leads to improved survival in patients with TBM. Indeed, Xpert 66 
MTB/RIF on sputum has reduced the time to diagnosis of pulmonary TB but has not 67 
improved morbidity or mortality.(5, 6)  Additionally, Xpert MTB/RIF requires electricity, 68 
disposable cartridges, and servicing that prevents its scale-up to rural areas.  69 
In contrast to TBM, cryptococcal meningitis diagnosis is facilitated by a simple low-cost 70 
lateral flow assay. One possible point-of-care candidate for the diagnosis of TBM is the LAM 71 
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lateral flow assay (LFA) which requires < 100 l of urine applied to a small test strip at room 72 
temperature. It has been used to detect disseminated TB with its greatest utility in HIV-73 
infected patients with severe immunosuppression. A large multicenter randomized 74 
controlled trial of urine LAM-guided initiation of anti-tuberculosis treatment in sub-Saharan 75 
on inpatients with suspected pulmonary TB showed a reduction in 8-week inpatient 76 
mortality.(7) In a proof-of-concept study, LAM ELISA testing of CSF on a cohort of South 77 
African adults with suspected TBM had a sensitivity of 64% and a specificity of 69% for the 78 
diagnosis of culture positive TBM.(8) An autopsy study of LAM LFA for the diagnosis of 79 
definite TBM showed a sensitivity of 75% and a specificity of 87%.(9) There has been no 80 
report of LAM LFA on urine or CSF in living patients for the diagnosis of TBM. 81 
We evaluated the diagnostic accuracy of Xpert MTB/RIF on CSF, LAM LFA on fresh urine 82 
and/or CSF, and current standard of care for TBM diagnosis in Zambia which combines 83 
clinical presentation with CSF glucose and total protein values. CSF M. tuberculosis culture 84 
served as the gold standard. We also studied whether use of Xpert MTB/RIF improved 85 
survival of TBM patients in a tertiary care facility in Zambia. 86 
Methods 87 
Study Design and Patient Population 88 
We conducted a prospective cohort study of TBM at the University Teaching Hospital (UTH) 89 
in Lusaka, Zambia between April 4, 2014 and August 31, 2017. We enrolled adults (age ≥ 18 90 
years) who presented with signs and symptoms concerning for TBM and already received a 91 
lumbar puncture as part of routine care. Patients with unknown HIV status were offered HIV 92 
testing as part of routine clinical care and not as part of the study. All potential study 93 
subjects were examined by a study neurologist. After a lumbar puncture was completed, 94 
study staff identified patients from the UTH microbiology laboratories who had ≥ 3 ml of 95 
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excess CSF remaining after routine testing composed of gram stain, India Ink stain, 96 
Cryptococcoal antigen testing, and bacterial culture on a blood agar plate. Mycobacteria 97 
growth indicator tube (MGIT) culture is currently not part of routine testing on all CSF. 98 
Patients with a positive CSF bacterial gram stain, India Ink stain, Cryptococcal antigen test, or 99 
positive bacterial culture were excluded from enrollment. A study nurse obtained written 100 
informed consent from the patient or health care proxy for study enrollment to use excess 101 
CSF from the lumbar puncture for additional M. tuberculosis  testing. No lumbar puncture 102 
was performed soley for study purposes or at the recommendation of study staff. The nurse 103 
also documented demographic data, presenting symptoms, past medical history, and 104 
medications through formal interview with the patient or health care proxy and review of 105 
the medical record as explicity requested in the consent form. Study subjects then provided 106 
an additional sample of whole blood and urine. A study neurologist conducted a structured 107 
neurologic assessment with particular attention to focal abnormalities.  We recorded 108 
Medical Research Council severity using the established grading system: grade I (GCS score 109 
15; no focal neurological signs), grade II (GCS score 11–14 or 15 with focal neurological 110 
signs), or grade III (GCS score ≤10).(10) Study staff recorded inpatient mortality. A study 111 
coordinator called patients or members of the household quarterly for one year to ask only 112 
about patient survival. The study was approved by the University of Zambia School of 113 
Medicine’s Biomedical Research Ethics Committee and Beth Israel Deaconess Medical Center 114 
Institutional Review Board. 115 
Laboratory testing      116 
Routine CSF testing at the UTH microbiology and biochemistry laboratories includes cell 117 
count, gram stain, India Ink stain, bacterial culture, fungal culture, total protein and glucose 118 
concentration.  When the UTH biochemistry laboratory did not have necessary reagents to 119 
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run CSF total protein, samples were processed at a private medical laboratory in Lusaka. 120 
Both the UTH laboratory and private laboratory are locally accredited. CSF Xpert MTB/RIF, 121 
CSF LAM, urine LAM, and CSF TB culture were performed in the Zambart research 122 
laboratories. 123 
Study staff delivered 3 ml of CSF and 3 ml of urine in plain sterile tubes in a cooler filled with 124 
ice packs to the Zambart research laboratories. In the laboratory, staff would bring the 125 
samples to room temperature 1 hour prior to use.  Using a sterile filtered tip pipette, a lab 126 
technician removed 60 µl of CSF and urine and transferred the specimens to a LAM LFA. 127 
When possible, two investigators blinded to clinical details and trained in LAM LFA 128 
interpretation read the samples after 25-35 minutes in comparison to a kit reference card 129 
according to manufacturer's instructions, and scored the test as positive, negative, or 130 
indeterminate. If there was disagreement, the lowest reading was taken as the final result. 131 
For 20% of the samples only one LAM LFA reader was available. Indeterminate samples were 132 
treated as negative for purposes of the analysis. 133 
The remaining CSF was centrifuged at 3500 g for 20 minutes. Supernatant was removed 134 
leaving a pellet and 500 µl of residual fluid. The samples were then vortexed. One hundred 135 
µl each was used to inoculate two separate MGIT tubes that were placed in a Bactec960 136 
instrument for culture. Samples postive on MGIT culture were confirmed as M. tuberculosis 137 
with the Capilia TB MPT64 Ag assay (Tauns Laboratories, Japan). Phosphate-buffered saline 138 
was added to the remaining CSF to bring it to a volume of 500 µl. Laboratory staff then 139 
added 1.5 ml of Xpert sample reagent. The specimen was incubated for 10 minutes at room 140 
temperature. The specimen was then either shaken vigorously for 20 seconds or vortexed 141 
for 10 seconds and was left to incubate for an additional 5 minutes. A laboratory technician 142 
then transferred 2 ml of specimen/sample reagent mixture to an Xpert cartridge for testing. 143 
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Results were rated as negative or positive for M. tuberculosis  with or without rifampicin 144 
resistance according to manufacturer's instructions. Samples found to be rifampicin resistant 145 
by Xpert MTB/RIF had confirmatory drug susceptibility testing (DST) for rifampicin and 146 
isoniazid conducted separately. Xpert MTB/RIF results were placed in the patient's file by 147 
study staff within 24 hours of the test being completed.  148 
Diagnostic categorization 149 
We classified patients as having definite or probable TBM to evaluate the performance of 150 
the Xpert MTB/RIF, CSF LAM, and Urine LAM. Definite TBM was defined as a CSF sample that 151 
was MGIT culture positive. Probable TBM was defined as patients with a CSF white blood 152 
cell count between 10-500, CSF total protein > 100 mg/dl, and CSF glucose < 40 mg/dl. This 153 
was adapted from a uniform case definition of probable TBM for use in clinical research.(11) 154 
Statistical analyses 155 
Descriptive measures (such as median, interquartile range, frequencies, and percentages) 156 
were used to summarize the data. Wilcoxon rank sum and Fisher exact tests were used to 157 
compare continuous and categorical, respectively, study variables between groups. 158 
The primary outcome of interest was the performance of Xpert MTB/RIF, CSF LAM, and urine 159 
LAM for the diagnosis of TBM relative to CSF MGIT culture as the gold standard. Sensitivity 160 
and specificity together with their corresponding 95% confidence intervals were calculated 161 
to assess the predictive accuracy of the diagnostic tests (CSF Xpert MTB/RIF, CSF LAM, urine 162 
LAM, CSF total protein and glucose) at specific thresholds.  Exact binomial confidence 163 
intervals were used to estimate confidence intervals for sensitivities, and specificities. 164 
Receiver operating characteristic (ROC) curves and the area under the ROC curves were used 165 
to evaluate and compare the overall predictive accuracy of the diagnostic tests. Secondary 166 
outcomes of interest were factors associated with inpatient and one-year mortality. 167 
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Univariate and multivariate logistic regression models were utilized to assess the clinical 168 
predictors of inpatient and one-year mortality. A significance level of <0.10 was used to 169 
select variables for the multivariate analyses. The inpatient mortality rate for the HIV-170 
infected TBM patients were compared to the inpatient mortality rate of HIV-infected TBM 171 
controls from a prior study at the same facility where PCR results were not readily available 172 
(12) to assess the impact of real-time use of CSF Xpert MTB/RIF.  All P values were 2-sided 173 
and considered statistically significant if <0.05.  174 
Results 175 
Patients characteristics 176 
Five-hundred and fifty patients were enrolled into the study as shown in Figure-1.  Of those, 177 
474 (86.2%) were HIV-infected. Eleven patients (2%) had an unknown HIV status because 178 
they either declined testing or died prior to testing. The incidence of TB culture positive CSF 179 
was higher among HIV-infected patients (20.5% vs 12.3%) though this difference was not 180 
statistically significant.  181 
Table 1 shows the patient demographics stratified by HIV status. The median age of patients 182 
who were TBM culture positive was significantly higher in HIV-positive patients compared to 183 
HIV-negative patients (P = 0.005). There were significantly more HIV-infected men 64/190 184 
(33.7%) than women 33/188 (17.6%) diagnosed with TBM (P = 0.006). There was no 185 
significant difference in CD4+ T-cell counts or age between these two groups. In HIV-186 
negative patients with TBM, the median CD4+ T-cell count was < 200 cells/µl and 187 
significantly less than HIV-negative patients without TBM.  Overall, more patients with a 188 
negative CSF culture had received a prior diagnosis of TB though this difference was only 189 
significant in the HIV-infected population. For those patients taking ART at the time of 190 
enrollment, TBM patients were on ART for a significantly shorter period than those who did 191 
 on A







































not have TBM. Fifty-one percent of HIV-infected men with TBM received their HIV diagnosis 192 
within one week of enrollment compared with 27% of females (P = 0.03). Among HIV-193 
infected patients with TBM, there was no significant difference between men and women 194 
for a prior diagnosis of TB, taking ART, or inpatient mortality.  195 
Accuracy of diagnostic tests for TBM  196 
The sensitivity/specificity for the diagnostic tests were CSF Xpert MTB/RIF 52.9%/94.2%, CSF 197 
LAM 21.9%/94.2%, urine LAM 24.1%/76.1%. The combination of  CSF glucose < 40 mg/dL 198 
and total protein > 100 mg/dL had sensitivity/specificity of 66.3%/90%. Figure-2 shows the 199 
received operating characteristic (ROC) curves with area under the curve (AUC) for CSF Xpert 200 
MTB/RIF, CSF LAM, Urine LAM, CSF glucose, and CSF total protein in comparison to the gold 201 
standard of CSF TB culture. The AUCs were as follows: CSF Xpert MTB/RIF 0.75 (0.69 - 0.81; P 202 
< 0.0001), CSF LAM 0.59 (0.54 - 0.64; P = 0.001), Urine LAM 0.53 (0.47 - 0.58; P = 0.94), CSF 203 
total protein 0.81 (0.76 - 0.87; P = 0.001), CSF glucose 0.84 (0.78 - 0.90; P < 0.0001). Based 204 
on the Youden Index, the optimal cut off values when equally weighting for sensitivity and 205 
specificity for the diagnostic tests with continuous variables were as follows: CSF glucose < 206 
36 mg/dl (sensitivity 75% specificity 87%), CSF total protein > 110 mg/dl (sensitivity 82% 207 
specificity 75%). Figure-2 also shows the performance of a diagnostic model that includes 208 
CSF Xpert MTB/RIF, CSF LAM, CSF total protein, and CSF glucose with an AUC of 0.90 (0.84 - 209 
0.94; P<0.0001).  210 
CSF LAM detected 5 cases missed by Xpert MTB/RIF. When both tests were used in 211 
combination in HIV-infected patients the sensitivity was 59.1% with a specificity of 93.2%. 212 
We identified 14 cases of probable TBM. The inclusion of these cases did not significantly 213 
change the performance of Xpert MTB/RIF, CSF LAM, or urine LAM for the diagnosis of TBM. 214 
Of the CSF LAM indeterminate samples, 8% (1/13) were CSF TB culture positive. Of the urine 215 
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LAM indeterminate samples 19% (3/16) were CSF TB culture positive. A sensitivity analysis 216 
treating these 4 indeterminate samples as positive did not significantly change the overall 217 
test performance for CSF or urine LAM.  218 
Inpatient and one-year mortality 219 
Table-2 demonstrates the risk factors for inpatient and one-year mortality. No patients were 220 
lost during the period they were hospitalized but 113/550 (20.5%) were lost to follow-up 221 
after 1 year post-discharge. One year mortality outcomes among those who could be 222 
tracked was 58.9%. A sensitivity analysis treating all lost to follow-ups as having survived 223 
showed a one year mortality rate of 46.7%. A sensitivity analysis treating all lost to follow-224 
ups as having died showed a one year mortality rate of 67.3%.  Longer time period since HIV 225 
diagnosis, longer duration of treatment with ART, and a higher CD4+ T-cell count at the time 226 
of hospitalization were associated with surviving to discharge. Positive CSF TB culture and a 227 
higher Medical Research Council (MRC) TBM severity grade (10) were associated with 228 
inpatient mortality. Higher CD4+ T-cell count was associated with lower odds of one-year 229 
mortality. TB positive CSF culture and higher MRC TBM severity grade were associated with 230 
higher odds of one-year mortality. In the multivariate analysis in Table-2 only the MRC grade 231 
remained significant for both inpatient mortality and one-year mortality. Higher CD4 count 232 
was associated with one-year survival on multivariate regression analysis. 233 
The cumulative inpatient and one-year mortality for TBM patients that were diagnosed as 234 
CSF Xpert MTB/RIF positive was 49% and 76%, respectively. This is in comparison to an 235 
inpatient and one-year mortality of 37% and 62% for patients that were Xpert MTB/RIF 236 
negative but CSF TB culture positive. These differences were not statistically significant. 237 
There was also no significant difference in MRC grade between CSF Xpert MTB/RIF positive 238 
and negative TBM patients. Xpert MTB/RIF detected rifampicin resistance on 6/55 (11%) 239 
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positive samples. The cumulative inpatient and one-year mortality for these patients was 240 
67% and 83%, respectively. The inpatient mortality of 49% in this study was not significantly 241 
different from the inpatient mortality of 46% from a prior study at the same institution 242 
where PCR results from TBM patients were not shared with the treating team in real 243 
time.(12)  244 
Discussion 245 
Xpert MTB/RIF performance and impact on mortality 246 
Xpert MTB/RIF performed similarly compared to what has been previously reported for the 247 
diagnosis of TBM.(13, 14) It misses almost half of definite TBM cases which results in 248 
frequent empiric treatment based on diagnostic algorithms or provider suspicion.  There 249 
was no difference in inpatient mortality among HIV-positive patients in this study when 250 
Xpert MTB/RIF results were turned over to the treating team within 24 hours compared to a 251 
prior PCR study in the same institution when results were not immediately available for 252 
clinical care purposes.(12) This may reflect the high rate of empiric treatment in cases that 253 
were Xpert negative. 254 
Utility of LAM and CSF Biochemistry 255 
CSF LAM testing was highly specific and detected 5 cases that were missed by Xpert 256 
MTB/RIF. The additional detection of cases by CSF LAM comes with little additional 257 
resources given LAM's cost and ease of use.  These findings highlight that there are novel 258 
CSF biomarkers for TBM that can be used to enhance the diagnosis. 259 
Based on the performance of urine LAM, it does not appear to be of value as a stand-alone 260 
test for the diagnosis of TBM. However, urine LAM was positive in 51 HIV-infected patients 261 
with CD4+ T-cell count < 200 who had a negative CSF culture. In a prior study, urine LAM had 262 
a sensitivity of 46% and a specificity of 93% for the diagnosis of disseminated TB in HIV 263 
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patients with advanced immunosuppression.(15) Thus, it is likely that the majority of these 264 
51 patients had disseminated TB with unclear CNS involvement. In a recently developed 265 
uniform case definition of TBM, clinical research patients have been assigned to categories 266 
of probable or possible TBM based on a numerical score derived from a combination of 267 
clinical presentation, CSF findings, neuroimaging, and evidence of TB elsewhere.(11) Urine 268 
LAM is currently not factored into this scoring system as evidence of TB elsewhere. Based on 269 
our findings, we feel it deserves strong consideration for inclusion. 270 
CSF glucose and total protein demonstrated the highest AUC compared with all of the other 271 
diagnostic tests. The optimal cutoff values of a CSF glucose < 36 mgl/dL and CSF total protein 272 
> 110 mg/dL established by the Youden Index when providing equal weight to sensitivity and 273 
specificity are consistent with the cutoff values established in the consensus paper for the 274 
diagnosis of TBM for clinical research.(11) It is important to note, that cryptococcal 275 
meningitis and bacterial meningitis patients were screened out in our population. 276 
High mortality 277 
The inpatient and one-year mortality among TBM patients was extremely high. MRC grade 278 
was the only significant factor associated with both inpatient and one-year mortality in the 279 
multivariate model suggesting that the major driver of mortality is the advanced stage of 280 
illness at the time of initial medical evaluation. Additionally, there were significantly more 281 
men than women diagnosed with TBM in this study. These findings support numerous 282 
research studies that document poor health seeking behavior among HIV-infected males 283 
resulting in presentation during advanced stages of illness.(16) 284 
HIV-negative TBM patients 285 
There was a relatively small number of HIV-negative patients diagnosed with TBM. These 286 
patients were younger than the HIV-positive population and had similarly low CD4+ T-cell 287 
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counts. The etiology for the CD4+ lymphocytopenia in this population was likely TB infection 288 
itself rather than another source of immunodeficiency.(17)  289 
Limitations 290 
This study has a number of limitations. There is stigma around lumbar punctures in Zambia 291 
that leads to a high refusal rate of nearly 25%.(18)  As a result, this cohort may not be 292 
representative of all patient with TBM but rather only those who provided CSF. This study 293 
used approximately 3 ml of centrifuged CSF for Xpert MTB/RIF testing. It has been shown 294 
that larger volumes of centrifuged CSF can increase Xpert MTB/RIF sensitivity.(19)   295 
Additionally, CSF TB culture is widely accepted to be an imperfect gold standard for the 296 
diagnosis of TBM especially in patients with paucibacillary disease in whom false negative 297 
cultures are likely problematic. As a result, the true performance of Xpert MTB/RIF, CSF LAM, 298 
and urine LAM are likely better than reported here. A consensus definition of probable and 299 
possible TBM was developed for clinical research in 2010.(11) Data collection in this study 300 
did not provide sufficient information to use the recommended definitions. An adapted 301 
definition of probable TBM was used and we did not classify patients with possible TBM.  302 
Future research 303 
GeneXpert MTB/RIF Ultra (Xpert Ultra) is the next generation Xpert MTB/RIF test that has 304 
shown increased sensitivity for the diagnosis of TBM. It has been endorsed by the WHO as 305 
the test of choice for the diagnosis of TBM.(20) A larger study that incorporates Xpert Ultra 306 
would be beneficial to see if it results in a decrease in TBM-associated mortality. In TB 307 
endemic settings, many TBM patients are empirically commenced on TB medication based 308 
on clinical presentation and limited laboratory data. It is possible that Xpert Ultra will make 309 
no difference on mortality in these settings. This is an important question given the 310 
significant financial resources Xpert Ultra requires for scale up in LMIC. 311 
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Figure Legends 422 
 423 
Figure 1 - Flow sheet of patient recruitment and percentages with positive CSF 424 
culture, CSF Xpert, CSF LAM, and urine LAM testing based on HIV status. 425 
 426 
Figure-1 - Abbreviations: TBM, tuberculous meningitis; MTB, Mycobacterium 427 
tuberculosis; Cx, culture; CSF, cerebrospinal fluid; Xpert, GeneXpert MTB/RIF; RIF, 428 
rifampicin; LAM, lipoarabinomannan. 429 
 430 
Figure-2: Receiver operating curves (ROC) for diagnostic tests to distinguish TBM 431 
from non-TBM cases. The model (blue line) demonstrates the area under curve 432 
incorporating all variables except for urine LAM. 433 
 434 

















































































Table 1 - Patient Demographics 
 




TBM culture  
negative 
(n=378) 







Age y, median 
(IQR) 
35 (30-41) 36 (30-43) 0.36 25 (24-27) 41 (28-55) 0.006 
Gender, male  64 (66%) 190 (50%) 0.006 3 (38%) 27 (47%) 0.88 
CD4+ T ells/μL, 
median (IQR) 
104 (45-167) 129 (42-346) 0.06 165 (142-264)  593 (498-842) 0.003 
Prior TB diagnosis  20 (21%) 163 (43%) < 0.0001 0 (0%) 5 (9%) 0.38 




14 (3-152) 270 (30-1825) < 0.0001 - - - 
Taking ART (%) 33 (34%) 231 (61%) < 0.0001 - - - 
Duration of ART, 
median days 
(IQR) 


































42 (43%) 83 (22%) 0.0002 2 (25%) 14 (25%) 0.68 
One-year 
Morality 
59 (61%) 165 (44%) 0.003 2 (25%) 26 (46%) 0.47 
 on A






































Abbreviations: MRC, Medical Research Council 











































































































Table 2 - Variables Associated with Inpatient and One-Year Mortality 
in Univariate and Multivariate Analysis 
 
 
 Univariate Analysis Multivariate Analysis 
Variable 
(N=550) 
Odds Ratio  
(95% CI) 




Categorical (n)     
  Female (261) 0.81 (0.56 - 1.19) 0.29   
  HIV (475) 1.02 (0.57 - 1.85) 0.93   
  Taking ART (190)  0.85 (0.57 -1.26) 0.42   
  History of TB (189) 0.75 (.50 - 1.12) 0.17   
  TB positive  
  CSF culture (107) 
2.51 (1.61 - 3.90) <0.0001 2.38 (0.92 - 
6.14) 
0.07 
Continuous     
  Age 0.99 (.97 - 1.0005) 0.19   
  Duration of 
  HIV diagnosis 
  (days) 
0.9995 (0.9993 - 
0.9998) 




  Duration of  
  ART (days) 
0.9996 (0.9994 - 
0.9999) 
0.02 1.0002 (0.9994 
- 1.000) 
0.60 
  CD4 0.9990 (0.9982 - 
0.9998) 
0.02 0.9996 (0.9981 
- 1.0012) 
0.70 
  MRC severity 2.933 (2.103 - 
4.091) 




Categorical (n)     
  Female (261) 0.82 (0.56 – 1.21) 0.32   
  HIV (475) 1.37 (.77 – 2.42) 0.28   
  Taking ART (190) 1.25 (.83 – 1.86) 0.28   
  History of TB (189) 1.47 (.97 – 2.24) 0.07 0.62 (0.35 - 
1.10) 
0.10 
  TB positive 
  CSF culture (107) 
1.68 (1.03 - 2.74) 0.04 1.28 (0.67 - 
2.43) 
0.45 
Continuous     
  Age 1.01 (.99 – 1.03) 0.33   
  Duration of 
  HIV diagnosis 
  (days) 
0.9998 (0.9996 – 
0.9999) 




  Duration of  
  ART (days) 
0.9999 (.9996 – 
1.0001) 
0.45   
  CD4 0.9985 (0.9978 – 
0.9993) 
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